| Active Not Recruiting | Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory NCT04756401 | Academic and Community Cancer Research United | Phase 2 |
| Recruiting | Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple NCT05363111 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma NCT05391750 | Emory University | Phase 1 |
| Active Not Recruiting | Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple M NCT05514990 | University of Southern California | Phase 1 / Phase 2 |
| Recruiting | Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With NCT05312255 | Roswell Park Cancer Institute | N/A |
| Active Not Recruiting | Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refracto NCT05411497 | Mayo Clinic | Phase 1 |
| Terminated | Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug ( NCT05288062 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma NCT04850599 | OHSU Knight Cancer Institute | Phase 2 |
| Terminated | Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies NCT05191472 | Alfred Chung, MD | Phase 2 |
| Terminated | Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refra NCT04956302 | Abdullah Khan | Phase 1 |
| Terminated | Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously U NCT04892264 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neop NCT04640779 | Mayo Clinic | Phase 1 |
| Terminated | Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple My NCT04407442 | University of California, San Francisco | Phase 2 |
| Recruiting | Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma NCT04508790 | City of Hope Medical Center | Phase 2 |
| Active Not Recruiting | Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in P NCT04205409 | University of Washington | Phase 2 |
| Completed | Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy NCT04409314 | University of California, San Francisco | — |
| Terminated | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial NCT03878524 | OHSU Knight Cancer Institute | Phase 1 |
| Withdrawn | Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refra NCT03856112 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multipl NCT03710421 | City of Hope Medical Center | Phase 1 |
| Completed | Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma NCT03829020 | Mayo Clinic | Phase 1 |
| Withdrawn | Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Re NCT03701321 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Pa NCT03763162 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma NCT03713294 | Mayo Clinic | Phase 2 |
| Terminated | Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemoth NCT03457142 | Roswell Park Cancer Institute | Phase 2 |
| Withdrawn | Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant NCT03328936 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Withdrawn | TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Re NCT03506802 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Completed | Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma NCT03267888 | Emory University | Phase 1 / Phase 2 |
| Terminated | BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent NCT03502577 | Fred Hutchinson Cancer Center | Phase 1 |
| Terminated | Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma NCT03333746 | Yvonne Efebera | Phase 2 |
| Terminated | Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma NCT03256045 | University of Washington | Phase 2 |
| Completed | Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple My NCT03338972 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chr NCT02948283 | City of Hope Medical Center | Phase 1 |
| Completed | Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multipl NCT03202628 | Mayo Clinic | Phase 2 |
| Completed | High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in P NCT03128359 | City of Hope Medical Center | Phase 2 |
| Recruiting | A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemi NCT03017820 | Mayo Clinic | Phase 1 |
| Withdrawn | Simvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory Multiple Myeloma NCT02971410 | Wake Forest University Health Sciences | EARLY_Phase 1 |
| Terminated | Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplan NCT03015792 | Mayo Clinic | Phase 1 |
| Completed | Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangemen NCT02765854 | Emory University | Phase 2 |
| Completed | Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subproto NCT04439214 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W) NCT04439240 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X) NCT04439305 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma NCT02509052 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Completed | Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patie NCT02506959 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple My NCT02514382 | University of Southern California | Phase 1 |
| Terminated | Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection NCT02109224 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multipl NCT02119468 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Completed | Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Mu NCT02095834 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Mye NCT01946152 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myelo NCT01794039 | Mayo Clinic | Phase 2 |
| Completed | Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma NCT02086552 | Mayo Clinic | Phase 2 |
| Completed | SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple M NCT01955434 | Mayo Clinic | Phase 2 |
| Completed | Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma NCT01989598 | National Cancer Institute (NCI) | Phase 2 |
| Completed | S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma NCT01903811 | SWOG Cancer Research Network | Phase 2 |
| Terminated | Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoi NCT01899326 | Albert Einstein College of Medicine | N/A |
| Completed | Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multip NCT01936090 | Mayo Clinic | Phase 1 |
| Completed | Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma NCT01842308 | Mayo Clinic | Phase 1 / Phase 2 |
| Terminated | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multip NCT01646762 | Mayo Clinic | Phase 2 |
| Completed | Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refra NCT01689987 | OHSU Knight Cancer Institute | Phase 1 |
| Completed | Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma NCT01533194 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leu NCT01372540 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple NCT01605032 | Albert Einstein College of Medicine | Phase 2 |
| Completed | Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib NCT01415882 | Mayo Clinic | Phase 2 |
| Completed | 90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Periphe NCT01503242 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma NCT01301807 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma NCT01326702 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Don NCT01163357 | City of Hope Medical Center | Phase 1 |
| Completed | Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple NCT01330173 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma NCT01251172 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01028716 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients NCT01008462 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma NCT01085214 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Tr NCT02353468 | University of Colorado, Denver | Phase 2 |
| Completed | Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myel NCT00966693 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by NCT00789776 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating NCT00793572 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant f NCT00445692 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple My NCT00450814 | Mayo Clinic | Phase 1 / Phase 2 |
| Completed | Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease i NCT00105001 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms NCT00082784 | National Cancer Institute (NCI) | Phase 1 |
| Completed | FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma NCT00066638 | National Cancer Institute (NCI) | Phase 2 |